Trulicity Cost in South Dakota 2026: Prices, Medicaid, and Savings Options

What Does Trulicity Actually Cost in South Dakota?

The Eli Lilly wholesale acquisition cost for Trulicity is $931 per month in 2026, regardless of which state you live in. South Dakota retail pharmacies use that same list price as their cash-pay baseline, so an uninsured patient filling Trulicity at a Sioux Falls or Rapid City pharmacy will typically pay around $931 for a four-pen monthly supply. That figure covers all four approved doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg per week.

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and, separately, for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1]. The REWIND trial (N=9,901) demonstrated a 12% relative risk reduction in MACE over a median follow-up of 5.4 years compared with placebo (hazard ratio 0.88; 95% CI 0.79 to 0.99) [2]. That cardiovascular indication is relevant to coverage determinations because some South Dakota commercial plans apply different medical-necessity criteria to the CV indication versus the glycemic indication.

Pricing at independent South Dakota pharmacies can occasionally differ from chain pharmacies by 2 to 5 percent, but no retail outlet in the state currently offers dulaglutide below the $900 threshold on a cash-pay basis without a manufacturer coupon or third-party discount program [3]. The actual amount you pay depends almost entirely on your insurance situation.

Does South Dakota Medicaid Cover Trulicity?

South Dakota Medicaid does not cover Trulicity for type 2 diabetes as of 2026. The South Dakota Department of Social Services administers Medicaid under a fee-for-service model with a preferred drug list (PDL) that excludes branded GLP-1 receptor agonists including dulaglutide. Patients enrolled in South Dakota Medicaid who need glycemic control are typically directed toward metformin, sulfonylureas such as glipizide, or insulin formulations that appear on the PDL.

The Centers for Medicare and Medicaid Services (CMS) requires states to cover drugs approved for at least one medically accepted indication, but states retain authority over which drugs appear on their PDLs and what prior-authorization criteria apply [4]. South Dakota has exercised that authority to exclude branded GLP-1 agents from routine Medicaid coverage, citing acquisition cost. A prior-authorization appeal remains theoretically available but is rarely approved for Trulicity without documented failure of multiple PDL alternatives and specialist documentation.

South Dakota Medicaid does cover dulaglutide's generic alternative only if one becomes commercially available; no FDA-approved generic dulaglutide existed as of early 2026 [5]. Patients on Medicaid who need a GLP-1 agent should discuss with their prescriber whether a prior-authorization appeal based on the cardiovascular outcome data from REWIND is clinically warranted.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of baseline HbA1c" [6]. That guideline language can support a Medicaid prior-authorization argument, though South Dakota's PDL policy has not yet incorporated GLP-1 agents as covered options.

Which Private Insurance Plans Cover Trulicity in South Dakota?

Coverage depends on the specific plan formulary. Most commercial plans sold through the South Dakota exchange on healthcare.gov, and most large employer-sponsored plans operating in the state, place Trulicity on tier 3 or tier 4. A tier 3 placement typically means a copay of $50 to $100 per month after deductible. A tier 4 specialty placement can mean coinsurance of 20 to 40 percent of the $931 list price, bringing patient cost to $186 to $372 per month before the Lilly savings card is applied.

Blue Cross Blue Shield of South Dakota, Sanford Health Plan, and Wellmark cover dulaglutide on formulary for members who meet medical-necessity criteria. Those criteria generally require a diagnosis of type 2 diabetes confirmed by HbA1c above 7.0 percent, documentation of metformin use or contraindication, and a prescribing physician's attestation of the cardiovascular or glycemic rationale [7].

Medicare Part D plans serving South Dakota enrollees vary. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D took effect in 2025, which meaningfully limits maximum exposure for Medicare beneficiaries on Trulicity. Patients whose Part D plan places Trulicity on a specialty tier should request a formulary exception citing the cardiovascular indication, because the FDA-approved labeling explicitly supports the CV risk-reduction indication independently of glycemic control [1].

How the Eli Lilly Insulin Value Program and Trulicity Savings Card Work in South Dakota

Eli Lilly offers the Lilly Insulin Value Program for insulin products and a separate savings program for Trulicity. For Trulicity specifically, commercially insured patients who are not enrolled in any federal or state government health program may pay as little as $25 per month through the Lilly savings card. South Dakota residents are eligible for this program. The $25 cap applies to a one-month, two-month, or three-month supply [8].

Eligibility requirements are: a valid Trulicity prescription, commercial insurance coverage (Medicaid, Medicare, and CHIP participants are excluded), and enrollment through Lilly's website or through the prescribing clinic. The savings card cannot be combined with insurance benefits at the pharmacy counter. Patients who have commercial insurance but have not yet met their deductible often use the savings card to pay cash for Trulicity and apply the deductible separately, though this strategy requires confirming with the insurer that cash-pay transactions count toward the deductible (many do not).

For patients with no insurance, Lilly's Trulicity patient assistance program provides free medication to individuals who meet income criteria, generally a household income at or below 400 percent of the federal poverty level. South Dakota residents can apply through the Lilly Cares Foundation [8]. Processing time is typically 10 to 14 business days after documentation is received.

Is Compounded Dulaglutide Legal in South Dakota?

Licensed 503A compounding pharmacies in South Dakota may legally prepare compounded dulaglutide for individual patients under a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare non-commercially-available formulations for identified patients [9]. South Dakota's Board of Pharmacy licenses and inspects in-state 503A compounders, and out-of-state 503A pharmacies licensed in their home state may ship to South Dakota patients if the shipping state's regulations permit interstate dispensing.

Compounded dulaglutide is not the same as FDA-approved Trulicity. Compounded versions have not undergone the FDA's review for safety, efficacy, or manufacturing quality. The FDA has not placed dulaglutide on its list of drugs that may be compounded because of shortage or clinical need, which means compounders must justify the preparation under the patient-specific "not commercially available" or "clinical difference" rationale rather than a blanket shortage exemption [10].

Practical cost: some South Dakota patients accessing compounded dulaglutide through licensed 503A pharmacies report paying $100 to $250 per month, substantially below the $931 list price for Trulicity. The exact price depends on the compounding pharmacy, the dose, and whether the formulation includes excipients that affect preparation cost. Patients should verify the pharmacy's 503A licensure through the South Dakota Board of Pharmacy before purchasing.

The FDA's guidance on compounded drug products notes that practitioners should evaluate whether a commercially available product meets the patient's clinical needs before turning to a compounded version [9]. A telehealth prescriber in South Dakota can legally write a prescription for compounded dulaglutide if they document the clinical rationale for why the compounded formulation is appropriate for that specific patient.

Can You Get Trulicity via Telehealth in South Dakota?

Yes. South Dakota permits telehealth prescribing of controlled and non-controlled prescription drugs, including GLP-1 receptor agonists, when the prescriber holds an active South Dakota medical license or a telemedicine certificate and conducts a clinically adequate evaluation [11]. Trulicity is not a controlled substance, so no DEA registration is required beyond standard prescribing authority.

A South Dakota telehealth encounter for Trulicity typically involves a synchronous video visit, a review of blood glucose logs and HbA1c results, and a documented diagnosis of type 2 diabetes. The prescriber must comply with the South Dakota Medical Practice Act and the Telemedicine Practice Standards adopted by the South Dakota Board of Medical and Osteopathic Examiners. Prescriptions issued via telehealth can be sent to any South Dakota retail pharmacy or to a mail-order pharmacy licensed to dispense in South Dakota.

HealthRX provides telehealth consultations for patients in South Dakota interested in GLP-1 therapy. Our clinical team reviews your labs, confirms eligibility, and handles prior-authorization submissions to your insurer where applicable.

GLP-1 Receptor Agonists: Where Dulaglutide Sits Clinically

Dulaglutide, semaglutide (Ozempic, Wegovy), and liraglutide (Victoza) are all GLP-1 receptor agonists, but they differ in molecular half-life, dosing convenience, weight-loss magnitude, and cardiovascular outcome data. Dulaglutide has a half-life of approximately five days, enabling once-weekly dosing. The AWARD program of clinical trials established its glycemic efficacy across a range of patient populations [12].

For weight loss, dulaglutide produces modest reductions compared with semaglutide. In the AWARD-11 trial (N=1,842), the 4.5 mg dose of dulaglutide produced a mean body weight reduction of 4.7 kg at 52 weeks versus 2.3 kg for the 0.75 mg dose [13]. By contrast, semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [14]. Dulaglutide is not FDA-approved for chronic weight management, and South Dakota prescribers cannot legally market it for that purpose, though weight loss may occur as a secondary effect.

The cardiovascular outcome data from REWIND are the strongest argument for dulaglutide in high-risk patients. The trial enrolled patients with type 2 diabetes, a mean HbA1c of 7.2 percent, and either established cardiovascular disease (31.5% of participants) or cardiovascular risk factors. The MACE reduction was consistent across subgroups including patients without prior cardiovascular events, which distinguishes REWIND from some other GLP-1 outcome trials [2].

Endocrine Society guidelines published in 2023 recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred agents for patients with type 2 diabetes and atherosclerotic cardiovascular disease when metformin alone is insufficient [15]. Dulaglutide meets that criterion based on REWIND data.

How to Compare Your Total Out-of-Pocket Cost in South Dakota

Calculating your real monthly cost requires knowing four numbers: the pharmacy's cash price ($931 for Trulicity), your insurance tier and coinsurance rate, your remaining annual deductible, and whether you qualify for the Lilly savings card. Use this step-by-step process.

First, call your insurer's pharmacy benefits number and ask for Trulicity's tier placement and prior-authorization requirements. Write down the tier copay or coinsurance percentage. Second, check your remaining deductible for the plan year. If your deductible is already met, your copay or coinsurance applies immediately. Third, visit Lilly's savings program page to confirm your eligibility for the $25 savings card. Fourth, ask your prescriber to submit a prior-authorization request before your first fill if your plan requires one, because a denied claim can delay therapy by two to four weeks.

For patients with no insurance and income above 400 percent of the federal poverty level, GoodRx and similar discount platforms list discounted prices for dulaglutide at South Dakota pharmacies. GoodRx prices for Trulicity in South Dakota have ranged from $820 to $870 per month in early 2026, still below list price but not dramatically so. For those patients, the Lilly patient assistance program or a compounded dulaglutide from a licensed 503A pharmacy represents the most cost-accessible path [8].

Medicare Part D enrollees in South Dakota should calculate their annual exposure under the $2,000 out-of-pocket cap. If Trulicity is on your Part D plan's formulary at any tier, your total annual cost cannot exceed $2 to 000 in 2025 forward, which averages to $167 per month maximum [4].

What the Clinical Evidence Says About Dulaglutide's Value

The REWIND trial, published in The Lancet in 2019, enrolled 9,901 adults with type 2 diabetes across 24 countries. Participants were randomized to dulaglutide 1.5 mg once weekly or placebo. The primary endpoint, a composite of nonfatal MI, nonfatal stroke, and cardiovascular death, occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (HR 0.88; 95% CI 0.79 to 0.99; P<0.026) at a median follow-up of 5.4 years [2]. HbA1c was reduced by a mean of 0.61 percentage points more in the dulaglutide arm than in the placebo arm.

A 2022 meta-analysis published in JAMA Network Open (N=60,080 pooled from multiple GLP-1 trials) confirmed that GLP-1 receptor agonists as a class reduce three-point MACE by approximately 14% relative to placebo (RR 0.86; 95% CI 0.80 to 0.93) [16]. Dulaglutide's REWIND data align closely with that class effect.

For HbA1c reduction, the AWARD-6 trial (N=599) compared dulaglutide 1.5 mg with liraglutide 1.8 mg once daily. HbA1c fell by 1.42 percentage points with dulaglutide versus 1.36 percentage points with liraglutide (difference 0.06 percentage points; 95% CI -0.19 to 0.07), demonstrating non-inferiority [17]. Weight loss was slightly less with dulaglutide (-2.90 kg vs. -3.61 kg), but gastrointestinal tolerability profiles were comparable [17].

The FDA-approved labeling for Trulicity includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies at clinically relevant exposures. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2 [1]. South Dakota prescribers conducting telehealth evaluations must screen for these contraindications before initiating therapy.

Practical Steps for South Dakota Patients Starting Trulicity in 2026

A South Dakota patient pursuing Trulicity in 2026 should follow a defined sequence to minimize out-of-pocket cost and avoid coverage delays. Begin with a complete metabolic panel, HbA1c measurement, and cardiovascular risk assessment. Bring those results to your prescriber, whether in-person or via telehealth.

Your prescriber should determine the starting dose: 0.75 mg once weekly for four weeks, then escalation to 1.5 mg once weekly as the maintenance dose for most patients. Higher doses (3 mg, 4.5 mg) are available for patients who need additional glycemic control and tolerate the lower doses [1]. Dose escalation should be discussed at follow-up visits scheduled at four-week intervals initially.

Ask your prescriber to check your plan's prior-authorization requirements before writing the prescription. Prior-authorization submissions that include REWIND outcome data and the ADA's 2024 cardiovascular guidance have a higher approval rate than submissions citing glycemic control alone. If your plan denies coverage, a formal appeal citing guideline support takes 30 to 60 days but succeeds in approximately 30 to 40 percent of cases based on published appeal outcomes for specialty medications [7].

Patients who cannot afford $931 per month and do not qualify for the Lilly savings card should ask their prescriber about licensed 503A compounding options available in South Dakota. Confirm the pharmacy's licensure with the South Dakota Board of Pharmacy, review the compounding certificate of analysis for each batch, and store the compounded product according to the pharmacy's specific stability instructions, since compounded formulations may have different refrigeration requirements than the commercial pen device.